Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Xia Wei, Xue Tan, Qinghu Guan, Ruizhi Zhang, Shiguang Lei & Shaofeng Wei. (2023) Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Michael Drummond & Milton C. Weinstein. (2021) The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom. Human Vaccines & Immunotherapeutics 17:11, pages 4603-4610.
Read now
Read now
Francesco Saverio Mennini, Chiara Bini, Andrea Marcellusi, Alessandro Rinaldi & Elisabetta Franco. (2018) Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Human Vaccines & Immunotherapeutics 14:8, pages 1867-1873.
Read now
Read now
Viviane Gresset-Bourgeois, Phillip S. Leventhal, Stéphanie Pepin, Rosalind Hollingsworth, Marie-Pierre Kazek-Duret, Iris De Bruijn & Sandrine I. Samson. (2018) Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert Review of Vaccines 17:1, pages 1-11.
Read now
Read now
Riju Ray, Gaël Dos Santos, Philip O. Buck, Carine Claeys, Gonçalo Matias, Bruce L. Innis & Rafik Bekkat-Berkani. (2017) A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Human Vaccines & Immunotherapeutics 13:7, pages 1640-1652.
Read now
Read now
Pieter T. de Boer, Britt M. van Maanen, Oliver Damm, Bernhard Ultsch, Franklin C.K. Dolk, Pascal Crépey, Richard Pitman, Jan C. Wilschut & Maarten J. Postma. (2017) A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 17:3, pages 249-265.
Read now
Read now
Anita J. Brogan, Sandra E. Talbird, Ashley E. Davis, Edward W. Thommes & Genevieve Meier. (2017) Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Human Vaccines & Immunotherapeutics 13:3, pages 533-542.
Read now
Read now
Ming-Chin Yang, Elise Chia-Hui Tan & Jian-Jhih Su. (2017) Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human Vaccines & Immunotherapeutics 13:1, pages 81-89.
Read now
Read now
Mathieu Uhart, Hélène Bricout, Emilie Clay & Nathalie Largeron. (2016) Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Human Vaccines & Immunotherapeutics 12:9, pages 2259-2268.
Read now
Read now
Articles from other publishers (22)
Diana Tavares, Helena Mouriño, Cristina Antón Rodríguez & Carlos Martín Saborido. (2022) Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population. Vaccines 10:8, pages 1285.
Crossref
Crossref
Maria Ganczak, Paulina Dubiel, Marzena Drozd-Dąbrowska & Marcin Korzeń. (2022) Does Vaccinating against Influenza in a Given Epidemic Season Have an Impact on Vaccination in the Next Season: A Follow-Up Study. International Journal of Environmental Research and Public Health 19:13, pages 7976.
Crossref
Crossref
Michael Maschio, Michele A. Kohli, Mansoor Ashraf, Michael F. Drummond, Milton C. Weinstein & Joaquin F. Mould-Quevedo. (2022) An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom. Vaccines 10:4, pages 599.
Crossref
Crossref
Min Joo Choi, Gyeongseon Shin, Daewon Kang, Jae-Ok Lim, Yun-Kyung Kim, Won Suk Choi, Jae-Won Yun, Ji Yun Noh, Joon Young Song, Woo Joo Kim, Sang-Eun Choi & Hee Jin Cheong. (2022) Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50–64 Years, and At-Risk Adults Aged 19–64 Years. Vaccines 10:3, pages 445.
Crossref
Crossref
Darya Pokutnaya, Matthew M. Loiacono, Helen Booth, Rachael Williams, Christopher Ma, James Parker, Hélène Bricout, Susan Farrow & Joshua Nealon. (2022) The impact of clinical risk conditions on influenza and pneumonia diagnoses in England: a nationally representative retrospective cohort study, 2010–2019. Epidemiology and Infection 150.
Crossref
Crossref
Yoshiyuki Sugishita & Tamie Sugawara. (2021) Effectiveness and cost-effectiveness of influenza vaccination for elderly people. Vaccine 39:52, pages 7531-7540.
Crossref
Crossref
Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Mansoor Ashraf, Michael F. Drummond & Milton C. Weinstein. (2021) The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom. Vaccines 9:6, pages 598.
Crossref
Crossref
Debbie Duncan. (2020) Who needs a flu vaccination in 2020?. Practice Nursing 31:Sup12, pages S5-S9.
Crossref
Crossref
Eun Joung Choi, Joo Hee Park & Byung Chul Chun. (2020) Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea. Vaccine 38:32, pages 5002-5008.
Crossref
Crossref
Chenyang Huang, Xiaofang Fu, Yuqing Zhou, Fenfang Mi, Guo Tian, Xiaoxiao Liu, Jie Wu, Cheng Ding, Danying Yan, Lanjuan Li & Shigui Yang. (2020) Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine 38:6, pages 1332-1344.
Crossref
Crossref
Gaia Bertoldo, Annalisa Pesce, Angela Pepe, Concetta Paola Pelullo & Gabriella Di Giuseppe. (2019) Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy. PLOS ONE 14:5, pages e0215978.
Crossref
Crossref
Yun-Kyung Kim, Joon Young Song, Hyeongap Jang, Tae Hyun Kim, Heejo Koo, Lijoy Varghese & Euna Han. (2018) Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. PharmacoEconomics 36:12, pages 1475-1490.
Crossref
Crossref
Jennifer A. Whitaker, Mitchell S. von Itzstein & Gregory A. Poland. (2018) Strategies to maximize influenza vaccine impact in older adults. Vaccine 36:40, pages 5940-5948.
Crossref
Crossref
José Antonio López Trigo, Rosa López Mongil, Alberto Mariano Lázaro, Gloria Mato Chaín, Norberto Moreno Villajos & Primitivo Ramos Cordero. (2018) Vacunación frente a la gripe estacional en las personas mayores. Evaluación de la vacuna tetravalente. Informe de posicionamiento. Revista Española de Geriatría y Gerontología 53, pages 185-202.
Crossref
Crossref
Shinya Tsuzuki, Markus Schwehm & Martin Eichner. (2018) Simulation studies to assess the long-term effects of Japan’s change from trivalent to quadrivalent influenza vaccination. Vaccine 36:5, pages 624-630.
Crossref
Crossref
Wanitchaya Kittikraisak, Piyarat Suntarattiwong, Darunee Ditsungnoen, Sarah E. Pallas, Taiwo O. Abimbola, Chonticha Klungthong, Stefan Fernandez, Suchada Srisarang, Tawee Chotpitayasunondh, Fatimah S. Dawood, Sonja J. Olsen & Kim A. Lindblade. (2017) Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age. PLOS ONE 12:8, pages e0183391.
Crossref
Crossref
Gemma E Shields, Jamie Elvidge & Linda M Davies. (2017) A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union. BMJ Open 7:6, pages e014847.
Crossref
Crossref
Christiaan Dolk, Martin Eichner, Robert Welte, Anastassia Anastassopoulou, Laure-Anne Van Bellinghen, Barbara Poulsen Nautrup, Ilse Van Vlaenderen, Ruprecht Schmidt-Ott, Markus Schwehm & Maarten Postma. (2016) Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. PharmacoEconomics 34:12, pages 1299-1308.
Crossref
Crossref
George J. Milne, Nilimesh Halder, Joel K. Kelso, Ian G. Barr, Jocelyn Moyes, Kathleen Kahn, Rhian Twine & Cheryl Cohen. (2016) Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study. Influenza and Other Respiratory Viruses 10:4, pages 324-332.
Crossref
Crossref
Aye M. Moa, Abrar A. Chughtai, David J. Muscatello, Robin M. Turner & C. Raina MacIntyre. (2016) Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine 34:35, pages 4092-4102.
Crossref
Crossref
Yukari Tsurudome, Kazuhiko Kimachi, Yusuke Okada, Kenta Matsuura, Yusuke Ooyama, Kayo Ibaragi, Yoichiro Kino & Kohji Ueda. (2015) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Microbiology and Immunology 59:10, pages 597-604.
Crossref
Crossref
Heather Torbic & Erin M. Roach. (2015) Current Influenza Vaccine Options for 2014. Current Emergency and Hospital Medicine Reports 3:3, pages 126-133.
Crossref
Crossref